SPARC signs licensing deal with Visiox for two ophthalmic drug candidates
Sun Pharma Advanced Research Company (SPARC) has signed a licensing agreement with Visiox Pharma to award exclusive worldwide rights (except for India and Greater China) ... Read More
SPARC succeeds in phase 3 trial of PDP-716 in glaucoma patients
Sun Pharma Advanced Research Company (SPARC) has succeeded in a phase 3 clinical trial for PDP-716 ophthalmic suspension, its investigational drug for the treatment of ... Read More